Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Loomis publishes Annual and Sustainability Report for 2022

Loomis’ Annual Report and Sustainability Report for 2022 is now available at www.loomis.com. Upcoming reporting dates: Interim Report January – March:                   May 4, 2023Interim Report January – June:                      July 21, 2023Interim Report January – September:           October 26, 2023  This press release is also available on the company’s website, www.loomis.com. April 3, 2023

AFRY publishes Annual- and Sustainability Report for 2022

AFRY has today published the Annual and Sustainability Report for 2022 and it is available on the company website afry.com .The Report presents the company’s performance during the year, sustainability work and updated business strategy. The strategy contains of six pillars that reflect the direction of our divisions and also how we build long term value by focusing on our clients, employees and operational excellence. “I am proud of how we at AFRY have navigated the year while, at the same time, strengthening our operations. We delivered strong organic growth with

Flowscape wins new business in Sweden

A large international consulting company selected Flowscapes solution for the hybrid way of working for their new office in Gothenburg. The solution includes room booking and management of work desks using Flowscapes smart USB sensors. The order value for the first year is 850,000 SEK (75,000 EUR) and thereafter 250,000 SEK (22,000 EUR) annually recurring."We are now experiencing an increasing demand for our solutions in Sweden. Companies are adapting to the new hybrid way of working , which means that staff work a few days a week from home. Many companies

Flex LNG – Mandatory notification of trade by PDMR

Hamilton, BermudaApril 3, 2023 Flex LNG Ltd. (the “Company”) has received trade notifications from the following persons discharging managerial responsibilities (“PDMRs”): Susan Sakmar, Director, has on March 31, 2023 purchased 500 shares on New York Stock Exchange for USD 33.5689 per share. Following the purchase, Mrs. Sakmar owns 1,000 shares in the Company. This notification has been publicly disclosed in accordance with Article 19 of the Market Abuse Regulation section 5-12 of the Norwegian Securities Trading Act.

Repurchase of Truecaller B shares in week 13, 2023

During 27 March 2023 and 31 March 2023 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 766,815 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 23 September 2022. The share buyback programme will be executed between 23 September and up until the 2023 AGM, is being carried out in accordance “Emittentregelverket”.   Truecaller B shares have been repurchased as follows: Date: Aggregated daily Weighted

NeoDynamics Announces Delivery of CorePulse Needles to 23 Hospitals

STOCKHOLM – April 3, 2023, NeoDynamics AB (publ) (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced that the first production run of its CorePulse needles has been shipped and is anticipated to arrive with UK and German customers this month.NeoDynamics is pleased it will now deliver CorePulse needles in April and VacuPulse needles by mid-year to the centres in Europe listed below. The following hospitals will receive deliveries in April 2023: UK

Bioservo signs distribution agreement with Assistive Innovations for sales of Carbonhand[®] in the Netherlands

Bioservo signs an agreement for the sale of Carbonhand[®] with Assistive Innovations BV in the Netherlands, an important market with good knowledge of and great interest in Carbonhand. After the recently completed iHand study, and other previous studies, conducted in the Netherlands, there is a great interest in Carbonhand among patients, clinics and rehabilitation clinics. The agreement gives us access to this important market for Carbonhand. Founded in 1989, Assistive Innovations BV is part of a group that was the world's first manufacturer of rehabilitation robots, at that time

Bravida Finland strengthens its service offering in southwestern Finland

Bravida Finland acquires the business operations of the company Turun LaatuSähkö Oy, thereby expanding in southwestern Finland. The company has a turnover of EUR 1.8 million and 12 employees.Turun LaatuSähkö Oy offers a wide range of electrical services. The company also works with the installation of information networks and security systems, industrial electrical installations and repair services. It is based in Turku and is primarily active in the Turku region. “Bravida has a clear growth strategy in Finland and this acquisition is a further step in Bravida’s geographical expansion in

Implantica announces Dr. med. Yves Borbély Presented his 3-year Data on RefluxStop[TM] []at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)

Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. Borbély from Inselspital, Switzerland’s largest University hospital, presented his successful RefluxStop 3-year data at SAGES conference in Montreal, Canada last week.Dr. med. Yves Borbély, Specialist in Visceral Surgery at the University Clinic for Visceral Surgery and Medicine Inselspital, Switzerland, presented during the Emerging Technology session his 3-year results with RefluxStop, titled; “Novel Device to Address Gastroesophageal Reflux Disease”. He highlighted

Teleste: Managers´ transactions – Harju, Esa

Teleste CorporationManagers´ transactionsApril 3, 2023, at 9:30 a.m. EEST TELESTE: MANAGERS´ TRANSACTIONS – HARJU, ESA   Teleste Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Esa Harju Position: Chief Executive Officer  Issuer: Teleste Oyj LEI: 743700CJRQRU0007GN59 Notification type: INITIAL NOTIFICATION Reference number: 28232/5/4 ____________________________________________ Transaction date: 2023-03-31 Outside a trading venue Instrument type: SHARE ISIN:

The recipe of Fazer’s beloved Geisha chocolate is changing: “We are responding to consumers’ wishes”

Fazer Geisha has been among Finns’ favourite chocolates since the 1960s, and now its recipe is being updated. Palm oil in the Geisha chocolate filling will become a thing of the past as, moving forward, it will be replaced by sustainably produced cocoa butter.The word “Geisha” refers to artist in Japanese. “Gei” means “art” and “sha” a skilled person. The updating of the recipe has also required skills and expertise. Cocoa butter proved to be the solution for updating the recipe without compromising the familiar soft flavour and texture. The Geisha recipe update is part of Fazer’s

Teleste: Managers´ transactions – Hyytiäinen, Juha

Teleste CorporationManagers´ transactionsApril 3, 2023, at 9:30 a.m. EEST TELESTE: MANAGERS´ TRANSACTIONS – HYYTIÄINEN, JUHA   Teleste Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Juha Hyytiäinen Position: Chief Financial Officer  Issuer: Teleste Oyj LEI: 743700CJRQRU0007GN59 Notification type: INITIAL NOTIFICATION Reference number: 28229/7/14____________________________________________ Transaction date: 2023-03-31 Outside a trading venue Instrument type: SHARE

Teleste: Managers´ transactions – Narjus, Hanno

Teleste CorporationManagers´ transactionsApril 3, 2023, at 9:30 a.m. EEST TELESTE: MANAGERS´ TRANSACTIONS – NARJUS, HANNO   Teleste Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Hanno Narjus Position: Other senior manager  Issuer: Teleste Oyj LEI: 743700CJRQRU0007GN59 Notification type: INITIAL NOTIFICATION Reference number: 28235/5/4 ____________________________________________ Transaction date: 2023-03-31 Outside a trading venue Instrument type: SHARE ISIN:

Ovzon expands its offering with partner Nigma Conseil through a follow-up order

Ovzon expands its On-the-Move (OTM) SATCOM-as-a-Service offering with the partner Nigma Conseil through an initial order at a value of MUSD 0.6. The order includes both industry-leading OTM terminals and dedicated solutions development and support.Ovzon received its first order from Nigma Conseil in December 2022 with an order value of MUSD 1. This follow-up order demonstrates Nigma’s dedication as a valued partner in bringing Ovzon solutions to customers with demanding and critical missions. The deliveries contain the newest variants of Ovzon’s OTM terminals, including technology and

XNK Receives EU Tissue Establishment Certificate

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control of the complete manufacturing chain, from withdrawal of blood from the patient at the clinic to the delivery of the finished autologous NK-cell based medicinal product.“This is another very important milestone for us. From a manufacturing viewpoint, we now have all the permits we need to launch clinical studies within EU. All building blocks are now completed to position us for significant value creation with three to four potential phase I/II

Ultomiris recommended for NMOSD EU approval

3 April 2023 07:00 BST   Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)   No relapses observed in pivotal trial of first and only long-acting C5 inhibitor, indicating potential to prevent long-term disability due to relapses   Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). If authorised,

BioStock Investor Pitch: ExpreS2ion Biotechnologies

Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest pipeline addition, the cytomegalovirus. The company is currently looking to raise 102 MSEK in a rights issue to finance the next step with the ES2B-C001 breast cancer vaccine. CEO Bent U. Frandsen tells us more about the ongoing activities in  BioStock Investor Pitch today at 08.45 am.See the presentation at biostock.se : https://www.biostock.se/2023/04/biostock-investor-pitch-expres2ion-biotechnologies-2/

AMF has assumed its ownership in Delcore Fastigheter

AMF assumed its ownership in Delcore Fastigheter on 1 April 2023.Delcore Fastigheter is a company that is jointly owned by ICA Real Estate and the occupational pensions company AMF, as announced by ICA Gruppen on 23 December 2022, see press release . The net effect of the transaction on the Group’s cash flow will be approximately SEK 3.8 billion during the second quarter of 2023. At the same time, the Group’s net debt (excluding ICA Bank and IFRS 16 lease liabilities) will

New lecanemab-data presented at the AD/PD™ 2023 conference

Stockholm, April 3, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD), at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™). The presentations included analyses of amyloid-related imaging abnormalities (ARIAs) with antiplatelet and anticoagulant therapy, the incidence of isolated ARIA-H, and health-related quality of life (QOL),

Presentation of Intrum’s results for January-March 2023

Intrum announces its interim results for January-March 2023 on 27 April at 7:00 a.m. CET. The report will be presented in an audiocast with teleconference at 9.00 a.m. CET the same day.At the audiocast, Intrum will be represented by Andrés Rubio, President & CEO, and Michael Ladurner, CFO. The presentation will be held in English. To participate via audiocast, please use this link . Via the audiocast you will be able to ask written questions. To participate via teleconference, please register here 

DanCann Pharma A/S presented their work to the Ministry of Foreign Affairs

COPENHAGEN, Denmark, April 03, 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or "the Company"), a Danish company powered by cannabinoids, hereby announces that on March 30th, the Company received a visit from the Ministry of Foreign Affairs, represented by the Danish export manager, a senior adviser from the embassy in the Czech Republic, and the head of the health department.Jeppe Krog Rasmussen, Louise Conradsen, and Morten Martinsen welcomed the Ministry of Foreign Affairs along with the rest of the DanCann Pharma team to their facility in Jutland. The purpose

Ranplan publishes the Annual Report for 2022

Cambridge UK, 3 April 2023 – Ranplan’s Annual Report for 2022 has been published. A copy of the document in English or Swedish is available under Investors/Financial on the company’s website, please see www.ranplanwireless.com/investors. For further information, please contact:Per Lindberg, CEOTel: +46 79 340 7592per.lindberg@ranplanwireless.comwww.ranplanwireless.com Certified AdviserFNCA Sweden AB, info@fnca.se, is the Company’s Certified Adviser at Nasdaq First North. The information was submitted for publication, through the agency of the contact person above, on 3

Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124

Uppsala, Sweden – April 3, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, is delayed to late 2024 from previously first half of 2024, if approved by the US Food and Drug Administration (FDA) according to their ordinary timelines.   The updated timeline follows unexpected technical issues with the equipment used for the secondary packaging process in the outsourced supply chain for OX124 and there is a need for qualification and documentation of the packaging process to meet the

There are no items matching the current filter
There are no more items matching the current filter
Back to top